ArticleEye (London, England)2024
Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study).
Article in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Real-World Utilization and Initial Experience with Aflibercept-ayyh (PAVBLUOphthalmology and therapy · 2026Article
- Real-world effectiveness and safety of ranibizumab biosimilar FYB-201 in Saudi Arabia (Ravegza) and Jordan (Uptera): a middle eastern extension of the FORCE study.Eye (London, England) · 2026Article
- Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study.Scientific reports · 2026Article
- Anti-VEGF Therapies in Retinal Disorders: Current Landscape and Future Directions.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Treatment-Naïve Diabetic Macular Edema (BIOS-DME Study).Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings - FORCE study.Eye (London, England) · 2025Article
- Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study).Eye (London, England) · 2025Observational
- Quantitative Assessment of En‑face OCT‑Derived Minimum Intensity Fluid Changes Following Ranibizumab Biosimilar Therapy in Macular Neovascularization Secondary to nAMD and PCV.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.